Johnson & Johnson (NYSE:JNJ – Get Free Report) posted its quarterly earnings data on Wednesday. The company reported $2.82 EPS for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11, RTT News reports. The company had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a return on equity of 36.79% and a net margin of 46.34%. The firm’s quarterly revenue was up 4.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.80 earnings per share. Johnson & Johnson updated its FY24 guidance to $9.97-10.07 EPS and its FY 2024 guidance to 9.970-10.070 EPS.
Johnson & Johnson Stock Down 0.8 %
Johnson & Johnson stock traded down $1.19 during trading on Friday, hitting $154.23. 2,638,000 shares of the company were exchanged, compared to its average volume of 7,301,116. The business’s 50 day moving average is $148.26 and its 200 day moving average is $153.40. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $175.97. The company has a market capitalization of $371.18 billion, a P/E ratio of 9.68, a PEG ratio of 2.76 and a beta of 0.52. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36.
Johnson & Johnson Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be issued a dividend of $1.24 per share. The ex-dividend date is Tuesday, August 27th. This represents a $4.96 annualized dividend and a yield of 3.22%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.
Analyst Ratings Changes
View Our Latest Stock Report on Johnson & Johnson
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
See Also
- Five stocks we like better than Johnson & Johnson
- Technology Stocks Explained: Here’s What to Know About Tech
- Is This Telehealth Stock a Buy After the Recent Pullback?
- When to Sell a Stock for Profit or Loss
- Safeguard Against Credit Card Risks with This Top Financial Stock
- Using the MarketBeat Stock Split Calculator
- Streaming Titan’s Stock Ready to Hit All-Time Highs This Year
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.